RADIONUCLIDE STUDIES USING TUMOR-SEEKING RADIOPHARMACEUTICALS IN THE DIAGNOSIS OF PROSTATE CANCER

<p><strong>Object: </strong>to evaluate the efficiency of prostate scintigraphy in the prebioptic diagnosis of prostate cancer (PC).</p><p><strong>Subjects and methods. </strong>Two hundred and two patients with suspected PC underwent comprehensive examination, including 99mTc-technetril prostate scintigraphy and a morphometric study of biopsy material columns. A computer program (official registration certificate No. 2007614475 dated October 24, 2007) was worked out and patented to calculate the intensity of accumulation of radiopharmaceuticals in different portions of the right and left prostate lobes.</p><p><strong>Results and discussion. </strong>When the division index point «pathological focus/background», 1.5; ≤ 1.5, healthy; &gt; 1.5 suspected prostate cancer was used, the sensitivity of prostate scintigraphy was 81.65%; its specificity was 87.1%; the diagnostic effectiveness was 84.37%.</p><p><strong>Conclusion: </strong>The application of prostate scintigraphy can improve indicators for early detection of PC, due to the purposeful detection of the points, enhance the effectiveness of biopsy, and, having more grounds than the early ones, to exclude this disease at the prebioptic stage. The method is noninvasive and can be used to monitor patients with suspected PC.